Pediatric Dermatology Unit, Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,
Department of Dermatology and Venereology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,
Dermatology. 2020;236(6):565-570. doi: 10.1159/000507808. Epub 2020 Jul 10.
Infantile hemangiomas (IHs) are the most common vascular tumors in children. In the past few years, topical beta-blockers (bBs) have been reported to be an effective treatment of superficial IHs.
We sought to evaluate the clinical effectiveness and safety profile of enhanced percutaneous delivery of bBs for the treatment of IH.
A retrospective study of all cases of IHs treated with enhanced percutaneous delivery of bBs between 2018 and 2019 was performed. Epidemiologic, clinical, and treatment data, including effectiveness score and safety, were reviewed.
The study included 11 patients with a total of 11 IHs. Of the total number of IHs, 7 (63.7%) showed a good response to treatment and 4 (36.3%) had a partial response; thus all patients (100%) had good or partial response to treatment. No systemic or local adverse effects were reported.
This is an uncontrolled retrospective study.
Enhanced percutaneous delivery of bBs is a safe and efficient topical therapy for IH.
婴儿血管瘤（IHs）是儿童中最常见的血管肿瘤。在过去的几年中，局部使用β受体阻滞剂（bBs）已被报道为治疗浅表 IHs 的有效方法。
我们旨在评估增强经皮递送 bBs 治疗 IH 的临床疗效和安全性。
对 2018 年至 2019 年期间接受增强经皮递送 bBs 治疗的所有 IHs 病例进行回顾性研究。回顾了包括疗效评分和安全性在内的流行病学、临床和治疗数据。
本研究共纳入 11 例患者的 11 个 IH。在总共的 IH 中，7 个（63.7%）对治疗有良好的反应，4 个（36.3%）有部分反应；因此，所有患者（100%）对治疗有良好或部分反应。未报告全身或局部不良反应。
这是一项无对照的回顾性研究。
增强经皮递送 bBs 是治疗 IH 的一种安全有效的局部治疗方法。
